Cancer Care Ontario | Cancer Care Ontario

271 Results

Guidelines and Advice

Referral of Suspected Lung Cancer by Primary Care Practitioners

Status: Current
ID: 24-2
Version: 2

Jan 2019

Guidelines and Advice

Combined Modality Radiotherapy and Chemotherapy in the Non-surgical Management of Localized Carcinoma of the Esophagus

Status: Education and Information
ID: 2-12
Version: 2

Oct 2013

Guidelines and Advice

Organizational Guideline for Gynecologic Oncology Services in Ontario

Status: In-Review
ID: 4-11

Jun 2013

Guidelines and Advice

Systemic Therapy for Advanced or Recurrent Endometrial Cancer and Advanced or Recurrent Uterine Papillary Serous Carcinoma

Status: In-Review
ID: 4-8
Version: 4

Jul 2019

Guidelines and Advice

The Use of Chemotherapy and Growth Factors in Older Patients with Newly Diagnosed, Advanced Stage, Aggressive Histology Non-Hodgkin's Lymphoma

Status: Education and Information
ID: 6-7 Version 2
Version: 2

Jun 2013

Guidelines and Advice

Altered Fractionation of Radical Radiation Therapy in the Management of Unresectable Non-Small Cell Lung Cancer

Status: Education and Information
ID: 7-12 Version 2
Version: 2

May 2013

Guidelines and Advice

The Prognostic Value of the DNMT3A Biomarker in Cytogenetically Normal Patients with Acute Myeloid Leukemia

Status: Archived
ID: MOAC 1

Nov 2013

Guidelines and Advice

Extra-corporeal Photopheresis in the Management of Graft-Versus-Host Disease in Patients who Have Received Allogeneic Blood or Bone Marrow Transplants: Recommendations

Status: Current
ID: SCT 5

Aug 2013

Guidelines and Advice

Stem Cell Transplantation in Primary Systemic Amyloidosis

Status: Current
ID: SCT-2
Version: 2

Nov 2019

Guidelines and Advice

PET Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July 2011 to June 2012

Status: Current
ID: PET 2012-1

Sep 2013

Guidelines and Advice

The Role of Octreotide in the Management of Patients with Cancer

Status: Archived
ID: 12-7

Jun 2013

Guidelines and Advice

Use of 5-HT3 Receptor Antagonists in Patients Receiving Moderately or Highly Emetogenic Chemotherapy

Status: Archived
ID: 12-3

Jan 2003

Referral of Suspected Lung Cancer by Primary Care Practitioners

Combined Modality Radiotherapy and Chemotherapy in the Non-surgical Management of Localized Carcinoma of the Esophagus

Organizational Guideline for Gynecologic Oncology Services in Ontario

Systemic Therapy for Advanced or Recurrent Endometrial Cancer and Advanced or Recurrent Uterine Papillary Serous Carcinoma

The Use of Chemotherapy and Growth Factors in Older Patients with Newly Diagnosed, Advanced Stage, Aggressive Histology Non-Hodgkin's Lymphoma

Altered Fractionation of Radical Radiation Therapy in the Management of Unresectable Non-Small Cell Lung Cancer

The Prognostic Value of the DNMT3A Biomarker in Cytogenetically Normal Patients with Acute Myeloid Leukemia

Extra-corporeal Photopheresis in the Management of Graft-Versus-Host Disease in Patients who Have Received Allogeneic Blood or Bone Marrow Transplants: Recommendations

Stem Cell Transplantation in Primary Systemic Amyloidosis

PET Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July 2011 to June 2012

The Role of Octreotide in the Management of Patients with Cancer

Use of 5-HT3 Receptor Antagonists in Patients Receiving Moderately or Highly Emetogenic Chemotherapy

Pages